OncoMatch/Pancreatic Cancer (PDAC)/BRCA2
Pancreatic Cancer (PDAC)BRCA2 Clinical Trials
Germline BRCA2 pathogenic variants are the most common hereditary cause of pancreatic cancer (~3–5% of PDAC) and predict sensitivity to platinum-based chemotherapy and PARP inhibition. Olaparib maintenance is FDA-approved for germline BRCA1/2-positive metastatic PDAC with response to first-line platinum. Active trials study PARP inhibitor combinations, somatic BRCA2 eligibility expansion, and neoadjuvant BRCA-targeted strategies.
Top recruiting BRCA2 Pancreatic Cancer (PDAC) trials
Ranked by phase and US site count.
See all trials matched to your profile →The Cancer of the Pancreas Screening-5 CAPS5)Study
Johns Hopkins University
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
AstraZeneca
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Exelixis
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
Dana-Farber Cancer Institute
Combination Therapy in Cancers With Mutations in DNA Repair Genes
University of California, San Francisco